AlconXSWX:ALCE +3.65%53 Buyback Yield % is 2.22 as of Jun. 25, 2026, which is 60% above its 10-year median of 1.39. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 346 Medical Devices & Instruments companies, Alcon ranks better than 88.44% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Alcon's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ALCE vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Alcon's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Alcon's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (XSWX:ALCE) has a Buyback Yield % of 2.22 as of Jun. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alcon and its competitors. This is 60% above median its historical median of 1.39. Over the past decade, Alcon's Buyback Yield % has ranged from 0.27 to 2.22. According to the industry distribution chart, Alcon ranks #40 out of 346 companies in the Medical Devices & Instruments industry, placing it in the top 11.6%.
Is Alcon's Buyback Yield % too high?
Alcon's current Buyback Yield % of 2.22 is 60% above median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 2.22. Based on the distribution chart, Alcon ranks #40 out of 346 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #40 out of 346 companies for Buyback Yield %. This places Alcon in the top 12% of its industry — outperforming the majority of peers. Historically, Alcon's own Buyback Yield % has ranged from 0.27 to 2.22 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alcon and its competitors. Alcon's current Buyback Yield % is 2.22, which is 60% above median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current Buyback Yield % is 2.22, which is 60% above median its 10-year median of 1.39. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current Buyback Yield % is 2.22 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALCE) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALCE:
Buyback Yield %: 2.22 (60% above median its 10-year median of 1.39)
GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score
Get the complete analysis for XSWX:ALCE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALCE has been successfully added to your 
